Northpond Ventures, LLC Candel Therapeutics, Inc. Transaction History
Northpond Ventures, LLC
- $27.7 Million
- Q3 2024
A detailed history of Northpond Ventures, LLC transactions in Candel Therapeutics, Inc. stock. As of the latest transaction made, Northpond Ventures, LLC holds 1,935,215 shares of CADL stock, worth $12.3 Million. This represents 48.35% of its overall portfolio holdings.
Number of Shares
1,935,215
Previous 1,935,215
-0.0%
Holding current value
$12.3 Million
Previous $12 Million
11.78%
% of portfolio
48.35%
Previous 41.58%
Shares
1 transactions
Others Institutions Holding CADL
# of Institutions
84Shares Held
15.3MCall Options Held
570KPut Options Held
203K-
Acorn Capital Advisors, LLC New York, NY2.58MShares$16.4 Million8.54% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.79MShares$11.4 Million0.0% of portfolio
-
Portolan Capital Management, LLC Boston, MA1.62MShares$10.3 Million0.59% of portfolio
-
Geode Capital Management, LLC Boston, MA904KShares$5.74 Million0.0% of portfolio
-
Black Rock Inc. New York, NY823KShares$5.23 Million0.0% of portfolio
About Candel Therapeutics, Inc.
- Ticker CADL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 28,891,900
- Market Cap $183M
- Description
- Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. The company develops CAN-2409, which is in Phase II clinical trails for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the...